Průběžná zpráva o klinickém hodnocení léčiva RASmiR 01.08.2022 – 31.07.2023
| Title in English | Interim Report on Clinical Drug Evaluation RASmiR 01.08.2022 – 31.07.2023 |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Web | RASMIR |
| Description | Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Phase II. This is the fourth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2022 – July 31, 2023. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 30 patients were enrolled to the study. |